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WHAT IS KNOWN ABOUT THIS TOPIC? 
x Ivacaftor is a new drug with a novel mode of action 
x It is licensed for CF patients with specific genotypes  
x Manufacturer-sponsored randomised controlled trials suggest a mean increase 
in FEV1 of 10.1 ± 10.7% 
 
 
WHAT THIS STUDY ADDS  
x In a ಯreal lifeರ setting we observed a mean increase in FEV1 of 7.1% at 1 year 
x In the short term at least, ivacaftor appears to be safe and effective in Scottish 
paediatric CF patients  6 years of age with the G551D mutation   
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
We reviewed the impact of ivacaftor on Scottish paediatric cystic fibrosis (CF) 
patients  6 years of age after 12 months of treatment. Statistically significant 
improvements in FEV1 and BMI and a reduction in sweat chloride, all comparable 
with previously published data [1-3] were observed.  The findings also suggested 
reduced use of intravenous antibiotics and oral antibiotics.  No significant adverse 
effects were observed but a possible association with cataract formation could not be 
excluded.  This review suggests that, in the short term at least, ivacaftor is effective 
and safe in paediatric patients  6 years of age with G551D. 
 
 
BACKGROUND  
The CFTR potentiator, ivacaftor, was granted a European license in July 2012 and 
became available to Scottish CF patients aged 6 years with the G551D mutation in 
early 2013. Efficacy and safety data had come from two, manufacturer sponsored, 
randomised controlled trials [1,2] with small patient numbers; 26 children aged 6 ± 11 
years and 19 young people 12 ± 17 years received the drug.   
As a new drug with a novel mode of action, it is important to monitor the outcomes of 
ivacaftor administration in children with CF post marketing.  In Scotland there is a 
high prevalence of the G551D mutation (11.19% compared to 5.7% in UK, data from 
CF Registry report 2014), and an established managed clinical network (SPCF MCN) 
that reduces clinical management variability through the development of agreed 
standards of care.  These factors make Scotland particularly suitable for a review of 
real life outcomes. 
 
 
METHODS 
Retrospective data on FEV1, weight, height, sweat chloride, antibiotic courses, and 
adverse effects were collected from all Scottish clinics delivering paediatric CF care 
using a standard form.  Data were anonymised and entered into an Excel spreadsheet 
for analysis.  Percent predicted FEV1 was calculated using Global Lung Initiative 
(GLI) references.  Standard deviation (Z) scores were calculated for weight, height 
and BMI to adjust for normal growth by age and gender.  The paired t-test was used 
to evaluate changes in mean values from baseline.  Ethics approval was not necessary 
in accordance with guidance issued by the NHS Research Ethics Service.  
 
 
RESULTS 
100% of data collection forms were returned.  Twenty-seven children attending 11 
clinics were identified.  One patient was excluded from analysis because he was 
wholly non-compliant with treatment.  He was a 15 year old boy with a background 
of mental health problems which impacted on his acceptance of all prescribed 
medications; there were no concerns about adverse effects.  Of the remaining 26 
children audited, 22 started treatment between January and March 2013, 1 started 
earlier on compassionate grounds, and 3 started later upon reaching their 6th birthday.  
The children had been on ivacaftor an average of 17.0 months (range 12 ± 22) when 
their data were submitted, and commenced treatment at a median age of  9.3 years 
(range 6.0 ± 14.6).  There was a female preponderance (69%).  All children had at 
least one copy of the G551D mutation.  The second gene was dF508 in 73%.  One 
child was homozygous for G551D.   One child was chronically and two intermittently 
infected with Pseudomonas aeruginosa at baseline.  Ninety-two percent of patients 
were pancreatic insufficient.  Two children (8%) had a diagnosis of CF liver disease 
as defined by best practice guidance.[4]  None of the children had CF-related 
diabetes.  Three children (12%) were on nutritional supplements.  Five (19%) were on 
regular intravenous antibiotics (given at set intervals as part of care package at 
discretion of responsible clinician).  Two children (8%) had type I diabetes mellitus, 
one of whom also had hypothyroidism.  There were no other significant co-
morbidities.   
 
The pre and post treatment results for FEV1, growth parameters and sweat chloride 
compared to published data are displayed in Table 1. 
 
Table 1: Pre- and post- treatment data compared to published data 
  
 Scotland (n=26) Davies et al (n=26) Ramsey et al (n=83) Rowe et al (n=151) 
 
Baseline 12 
months 
Mean 
change 
P value Baseline 48 
weeks 
Mean 
change 
Baseline 48 
weeks 
Mean 
change 
Baseline 6 
months 
Mean 
change 
FEV1 % predicted 
Mean 
Range 
 
85.1 
28.4 ± 
107.5 
 
92.2 
45.1 ± 
108.2 
 
7.1 
 
<0.001 
 
84.7 
52.4 ± 
133.8 
 
95.4 
 
10.7 
 
63.5 
37.3 ± 
98.2 
 
73.6 
 
10.1 
 
82.6 
 
90.1 
 
6.7 
Weight 
Mean (kg) 
Range 
 
 
Z score (mean) 
Range 
 
32.2 
17.8 ± 65.0 
 
 
0.03 
-1.9 ± 2.0 
 
39.0 
19.7 ± 
86.1 
 
0.48 
-1.8 ± 2.2 
 
6.8 
 
 
 
0.45 
 
 
<0.001 
 
 
 
<0.001 
 
31.8 
18.8 ± 
62.6 
 
 
 
 
5.9 
 
61.7 
30.2 ± 
107.2 
 
64.8 
 
3.1 
 
55.2 
 
56 
 
 
2.5 
Height 
Z score 
Range 
 
-0.11 
-2.0 ± 2.1  
 
0.14 
-1.7 ± 2.1 
 
0.25 
 
=0.009 
         
BMI 
Mean (kg/m2) 
Range 
 
 
Z score (mean) 
Range 
 
17.2 
13.5 ± 23.8 
 
 
0.15 
-1.5 ± 2.2 
 
18.7 
13.5 ± 
26.5 
 
0.57 
-1.7 ± 2.3 
 
1.5 
 
 
 
0.42 
 
 
<0.001 
 
 
 
<0.001 
 
17.1 
14.2 ± 
26.0 
 
0.09 
-1.5 ± 2.1 
 
 
 
 
 
0.4*  
  
21.7 
14.8 ± 
38.9 
 
 
   
21.3 
 
21.7 
 
0.8 
Sweat chloride 
(mmol/L) (n=18) 
Mean 
Range 
 
 
112.1 
90.5 ± 
148.0 
 
 
47.6 
13.0 ± 
73.0 
 
 
-64.5 
 
 
<0.001 
 
 
104.3 
54 ± 128 
  
 
-56 
 
 
100.4 
74.5 ± 
128.0 
 
 
 
 
 
-48.7 
 
 
102.9 
 
 
49.1 
 
 
-53.8 
 
*This is an approximation taken from a graph within the paper 
 
Three children were overweight at baseline and remained so.  Three, who were of 
healthy weight at baseline, became overweight (as defined by the International 
Obesity Task Force).   
 
Eighteen children had sweat chloride measured at baseline and on treatment.  It 
remained > 60mmol/L (diagnostic range for CF) in 5 children (28%).  Mean increases 
in FEV1 and BMI within this group were 4.2% and 1.52 kg/m2 respectively. 
 
The G551D homozygote was a 6 year old boy with an FEV1 of 98.1% predicted and a 
BMI of 15.7 kg/m2 at baseline.  These parameters were essentially unchanged after 
one year of treatment however sweat chloride fell from 106mmol/L to 13mmol/L 
which was the lowest measurement in the whole group.  
 
Other clinically significant findings were: of the 5 children receiving regular IV 
antibiotics at baseline, 1 child was able to stop and 2 had the frequency reduced; 7 
(27%) required fewer courses of oral antibiotics for mild respiratory exacerbations; 
and 7 (27%) were able to reduce their dose of pancreatic enzyme replacement therapy 
(PERT), a change that was overseen by a dietitian in all cases.   
 
Possible adverse effects reported included transient headaches (n=1), transient 
unilateral ear swelling (n=1), and non-visually significant cataracts with no clear 
cause, detected 2 - 3 months into treatment with ivacaftor in 2 out of the 12 patients 
who had ophthalmological screening examinations.  Liver function tests were 
monitored regularly by all clinics with no clinically significant derangements 
observed. 
 
 
DISCUSSION 
The findings of this review of a Scottish paediatric population, in keeping with 
published data, show statistically significant improvements in FEV1 and BMI, and a 
reduction in sweat chloride after 12 months treatment with ivacaftor.  Similarly there 
were observed reductions in the number of courses of antibiotic therapy and PERT 
dose. 
 
The mean absolute increase in FEV1 of 7.1% was lower than that reported in the 
randomised phase 3 trials (10.7% for 6-11 year olds [1] and 11.4% for 12-17 year olds 
[2]) and patients aged ุ6 years real-world outcomes being studied at Cork University 
Hospital [5] (10.26%), but similar to the post approval evaluation of ivacaftor 
published by Rowe et al [3] (6.7%).  It is, perhaps, not surprising that our ಯreal lifeರ 
data are slightly less compelling than data gained from tightly controlled clinical 
trials.  Factors that could contribute to the difference include reduced patient 
adherence to treatment, no exclusion criteria (inhaled hypertonic saline was not 
discontinued, 1 child had low baseline FEV1 of 30% and 1 had high baseline FEV1 > 
105%), and the use of different lung function reference equations for calculating 
percent predicted values.  We used GLI references whereas the phase 3 trials used 
Knudson, and Rowe et al used Wang. 
 
 
The increase in weight and BMI observed in our population was similar to that 
reported by Davies et al [1] and one might expect Roweಬs cohort to be similar at one 
year considering their 6 month data [3].  Three children in our group became 
overweight over the course of their year on ivacaftor.  The adverse effects of being 
overweight/obese on long term general health for patients with CF are now becoming 
topical.  The nutritional status of patients on ivacaftor will need to be monitored 
closely and dietetic advice tailored accordingly. Information from the All Wales Adult 
CF Centre [6] is reassuring and indicates that increase in weight is mainly fat free 
mass, but there are no comparative data for children and fat free mass data were not 
collected in this review.  
 
No significant adverse effects were noted. The association of cataract formation and 
ivacaftor in animal models led 5 of the 11 Scottish clinics to perform eye screening 
during the review. It is unknown whether the 2 children with non-visually significant 
cataracts had them before or developed them during treatment.  A formal 
recommendation to carry out baseline and follow up ophthalmological examinations 
for all paediatric patients initiating treatment with ivacaftor has now been added to the 
Summary of Product Characteristics by the manufacturer. 
 
In conclusion, this review suggests that in the short term at least, ivacaftor is effective 
and safe in paediatric CF patients  6 years of age with G551D in Scotland.  
Continued monitoring is required to inform on long term efficacy and safety. 
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